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Rational prescribing of anti-epilepsy drugs in children may be complicated by a number of problems, which 
include: (i) difficulties in arriving rapidly at a syndromic diagnosis, at least in some cases, with consequent 
uncertainties about herapeutic management; (ii)difficulties in evaluating drug response in young age groups, 
particularly with respect to subjective side-effects affecting cognitive function; (iii) the vulnerability ofinfants 
and children to specific aspects of drug toxicity, such as liver damage induced by valproic acid or behavioural 
disorders caused by barbiturates; and {iv) the need to adjust dosage to account for age-dependent pharmaco- 
kinetic changes. In particular, it is known that the rate of drug metabolism changes markedly during develop- 
ment. Metabolic drug elimination isoften reduced at birth, but drug metabolizing enzymes mature rapidly and 
biotransformation n infants and children usually occurs at a faster ate than in adults. The elimination of 
drugs which are excreted unchanged in urine appears to be less influenced by age in paediatric patients, 
though impairment in renal drug clearance may be seen in newborns. Monitoring of serum drug concen- 
trations may be helpful for dosage adjustments, but it is not a substitute for careful clinical observation. 
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INTRODUCTION 
In most cases, epilepsy has its onset in infancy 
and childhood. Although some syndromic 
forms (most notably the idiopathic partial 
epilepsies) may not always require drug treat- 
ment, the vast majority of children need appro- 
priate pharmacological therapy to prevent 
recurring seizures. 
The drug treatment of epilepsy in infancy 
and childhood is associated with specific prob- 
lems which may not be encountered in an adult 
population. These problems encompass a wide 
range of diagnostic, therapeutic and pharma- 
cokinetic aspects which need to be taken into 
consideration for rational drug selection and 
the individualization of dose. 
DIAGNOSTIC CONSIDERATIONS 
Adequate therapeutic management is criti- 
cally dependent on the physician's ability to 
make a correct diagnosis. Many epileptic syn- 
dromes of infancy and childhood may not be 
easily diagnosed at their onset, and a mis- 
classification of seizure type or syndromic form 
may lead to inappropriate treatment. For 
example, carbamazepine may be ineffective 
and even worsen myoclonus and absences in 
adolescents with juvenile myoclonic epilepsy. 
Unfortunately, it is not always possible to 
exclude this syndrome in a teenager who 
presents with only one or two tonic-clonic seiz- 
ures, because absences and myoclonus may 
appear later, sometimes after starting carba- 
mazepine therapy 1.
DIFFICULTIES IN EVALUATING DRUG 
RESPONSES 
For obvious reasons, the recognition of subjec- 
tive adverse ffects of drug treatment may be 
particularly difficult in infants and young chil- 
dren. Careful observation by the physician, 
1059-1311/95/020139 +05 $08-00/0 © 1995 British Epilepsy Association 
140 E. Perucca 
parents and teachers is required to unmask 
subtle but potentially important detrimental 
effects on mood, performance and behaviour. 
Barbiturates are particularly prone to ad- 
versely affect cognitive function and behav- 
iour 2-4, but adverse central nervous system 
effects may also be encountered to a lesser 
extent with other drugs. 
AGE-RELATED CHANGES IN DRUG 
RESPONSIVENESS 
The adverse ffect profile of many anti-epilepsy 
drugs differs in children and adults (Table 1). 
For example, newborn babies of mothers 
treated with anti-epilepsy drugs (particularly 
phenytoin and barbiturates) are at risk of de- 
veloping a potentially fatal coagulation dis- 
order unless prophylactic treatment with 
vitamin K is given to the baby at birth, or to 
the mother during late pregnancy 5. Surpris- 
ingly, anti-epilepsy drugs do not appear to 
cause such coagulation disorders in adult 
patients. 
Table 1 : Examples of adverse effects of anti-epilepsy drugs 
occurring more often in infants and children than adults 
Drug Adverse ffect 
Barbiturates 
Benzodiazepines 
Phenytoin 
Valproic acid 
Fatal haemorrhage in newborn babies 
of treated mothers 
Irritability, hyperkinesia, behavioural 
problems 
Irritability, hyperkinesia, behavioural 
problems 
Fatal haemorrhage in newborn babies 
of treated mothers 
Coarse facial features, ache, hirsutism 
Enhanced susceptibility to liver damage 
AGE-RELATED DIFFERENCES IN 
PHARMACOKINETICS 
The possibility of achieving optimal seizure 
control depends not only on choosing the cor- 
rect agent, but also on identifying the best dose 
to fulfil individual needs. This is most import- 
ant in children because dose requirements may 
vary with time due to increasing body weight 
and pharmacokinetic hanges that occur 
during development. Hence, an understanding 
of the clinical pharmacokinetics of anti- 
epilepsy drugs in infants and children is essen- 
tial for rational prescribing. 
Absorption 
The gastrointestinal bsorption of many drugs 
is erratic in neonates but rapidly becomes more 
efficient during postnatal development. In 
infants and children, the oral bioavailability of 
anticonvulsants is similar to that observed in 
adults 6. It should be remembered, however, 
that the rate of drug absorption is often 
enhanced after intake of liquid formulations, 
which are often used in children. 
A parenteral route may be indicated when a 
rapid effect is required (as with intravenous 
diazepam to treat status epilepticus), when a 
child is unable to take the medicine orally, or 
when gastrointestinal absorption is inefficient, 
such as with phenobarbitone in the newborn. 
For many drugs, such as diazepam and pheny- 
toin, absorption from intramuscular sites tends 
to be slow and erratic. Rectal administration of
diazepam in solution produces serum drug 
levels above the anticonvulsant hreshold 
within a few minutes v.
Another example of altered rug responsive- 
ness in paediatric patients is represented by 
the high incidence of irritability, hyperkinesia 
and other behavioural disturbances in infants 
and children treated with barbiturates and 
benzodiazepines. Similarly, children aged 2 
years or younger are known to be at much 
greater risk of developing valproate-induced 
liver damage. 
Certain adverse effects of anti-epilepsy 
drugs may occur at any age but acquire special 
relevance in childhood. For example, pheny- 
toin-induced hirsutism and gum hyperplasia 
has greater psychosocial implications in a 
young girl than in an elderly male. 
Distribution 
The plasma protein binding of phenytoin, phe- 
nobarbitone and valproic acid may be reduced 
in the neonate, particularly in those born 
prematurely. Since only the free, non-protein- 
bound drug is pharmacologically active, this 
phenomenon must be taken into account when 
interpreting serum drug concentrations in 
clinical practice. In fact, because of the in- 
crease in free fraction, the total (free plus 
protein-bound) rug concentration required for 
an optimal response may be lower in newborn 
than older patients 6. This is particularly true 
for drugs such as phenytoin and valproic acid, 
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Table 2: Routes of elimination and plasma half-lives of anti-epilepsy drugs in the newborn, children and adults. For drugs which 
are metabolized, the shortest half-lives are generally observed in patients receiving concurrent reatment with enzyme-inducing 
anticonvulsants. Modified from Perucca 8 
Drug Main route of elimination Elimination half-life (hours) Optimal serum concentration 
Newborns Children Adults 
Carbamazepine 
Clonazepam 
Diazepam 
Ethosuximide 
Felbamate 
Gabapentin 
Lamotrigine 
Oxcarbazepine 
Phenobarbitone 
Phenytoin 
Primidone 
Valproic acid 
Vigabatrin 
Metabolic 8-35* 3-15" 5-25* 
Metabolic 20-45 20-30 25-40 
Metabolic 18-100 8-30 20-70 
Metabolic 35-60 20-50 40-70 
Metabolic + renal - -  - -  10-20 
Renal - -  - -  5-7 
Metabolic - -  7-90t  10-90t 
Metabolic - -  - -  10-275 
Metabolic + renal 60-400 40-80 60-140 
Metabolic Half-life dose-dependent§ 
Renal + metabolic 10-35 4-15 5-20 
Metabolic 10-70 4-15 5-18 
Renal - -  4-7 5-8 
<~47 ~mol/litre 
Serum level monitoring not indicated 
Serum level monitoring not indicated 
~<700 ~mol/litre 
NE 
NE 
NE 
NE 
~<170 ~mol/litre 
~<80 ~mol/litre 
Monitor serum phenobarbitone 
<~700 pxmol/litre 
Serum level monitoring not indicated 
* Carbamazepine metabolism undergoes autoinduction. A longer half-life is described after a single dose. 
* Shortest half-lives are observed in patients on concurrent treatment with enzyme-inducing anticonvulsants. Longest 
half-lives are observed in patients treated with valproic acid in combination. 
Half-life refers to active metabolite 10-hydroxycarbazepine. 
§ Phenytoin half-life increases with increasing serum concentrations of the drug l in children, from about 10 hours at low 
concentrations to about 20 hours at therapeutic concentrationsl. E imination is faster in children than in adults. 
NE Usefulness of serum level monitoring has not been established. 
which are more extensively bound to plasma 
proteins. 
Elimination 
The elimination half-life of most anticonvul- 
sants is prolonged in neonates as a result of 
immaturity of the drug metabolizing enzymes 
and/or renal excretion mechanisms (Table 2). 
In the case of enzyme-inducing drugs Ibarbitu- 
rates, phenytoin, carbamazepine), transpla- 
cental induction may occur and metabolic drug 
elimination may be more efficient in neonates 
exposed to the drug in utero compared to non- 
exposed neonates 9. 
The activity of the drug metabolizing 
enzymes increases rapidly during postnatal de- 
velopment and, within a few weeks or months, 
reaches levels generally higher than in adults 
(Table 2). To compensate for the increased 
elimination, older infants and children usually 
require maintenance doses which are consider- 
ably higher (when expressed as mg/kg) than 
those used in adults 1°. Moreover, for drugs 
such as carbamazepine and phenytoin, the 
shorter elimination half-lives in paediatric 
patients imply that more frequent daily ad- 
ministration is required to minimize fluctu- 
ations in drug serum levels between doses. 
Since metabolic changes occur at different ages 
in different patients, the degree of pharmaco- 
kinetic variation tends to be greater in chil- 
dren than in adults, and individualization of
dose may be particularly difficult. Moreover, 
because of the age-related metabolic hanges, 
dose adjustments in the same patient cannot be 
based simply on the increase in body weight. 
Careful monitoring of clinical response, some- 
times aided by serum drug level measure- 
ments, is required to determine the need for 
dose modification. 
In general, the elimination of drugs which 
are excreted unchanged in urine {for example, 
vigabatrin} appears to be less influenced by age ° 
changes in paediatric patients. An impairment 
in renal drug clearance, however, may be 
expected in neonates, especially in those born 
prematurely. 
ANTI-EPILEPSY DRUG INTERACTIONS 
Although most children with epilepsy can be 
treated satisfactorily with a single drug, some 
patients require combination therapy and are 
therefore at risk of potentially adverse drug 
interactions. Interactions may also occur with 
drugs used for unrelated medical conditions. 
Pharmacokinetic drug interactions 
These interactions may affect absorption, dis- 
tribution or elimination processes (Table 3}. 
The interaction between phenytoin and val- 
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Table 3: Examples of clinically relevant drug interactions which may occur in children with epilepsy. For a comprehensive list, 
see Pisani et aL 1' and Brodie '2 
Interfering drug Affected drug Consequence 
Salicylic acid, valproic acid 
Phenytoin, phenobarbitone, 
primidone 
Carbamazepine, phenytoin, 
phenobarbitone, primidone 
Vigabatrin 
Phenytoin 
Valproic acid 
Valpromide 
Carbamazepine, phenytoin, 
phenobarbitone, primidone 
Cimetidine, rythromycin, 
d-propoxyphene, isoniazid 
(and many others) 
Phenytoin 
Carbamazepine 
Valproic acid, lamotrigine, 
benzodiazepines, ethosuximide 
Phenytoin 
Phenobarbitone 
Phenobarbitone, lamotrigine 
Carbamazepine 
Dexamethasone, pr dnisolone, 
warfarin, doxycycline 
haloperidol, theophylline 
Carbamazepine 
Phenytoin sdisplaced from plasma protein binding sites. 
Total serum phenytoin levels underestimate th level of 
free, pharmacologically ctive drug. 
Serum carbamazepine levels are reduced due to enzyme 
induction. Carbamazepine dose requirements may 
increase. 
Serum levels of affected drug may decrease due to enzyme 
induction. Dose requirements may increase accordingly. 
Serum phenytoin levels may decrease. 
Serum phenobarbitone levels may increase due to 
metabolic inhibition with attendant risk of intoxication. 
Serum phenobarbitone a d lamotrigine l vels increase due 
to metabolic inhibition, with attendant risk of 
intoxication. 
Serum levels of the active metabolite carbamazepine- 
10,11-epoxide ncrease markedly and may precipitate 
signs of intoxication. 
Serum levels of affected drug may decrease due to enzyme 
induction. Dosage requirements may increase accordingly. 
Serum concentrations f affected drug may increase due to 
metabolic inhibition, with attendant risk of intoxication. 
proic acid is a good example of the events 
which occur when there is drug displacement 
from plasma protein binding sites. The dis- 
placed drug (phenytoin) undergoes rapid elim- 
ination and redistribution into the tissues, 
resulting in decreased total serum concen- 
trations. The concentration of free, pharmaco- 
logically active drug is, however, unaltered or 
may be even slightly increased. This interac- 
tion does not usually affect clinical response, 
but should be taken into account when inter- 
preting serum phenytoin levels in clinical 
practice. In fact, total serum phenytoin 
measurements in valproate-treated patients 
underestimate the level of free, pharmacologi- 
cally active drug and, despite the fall in total 
drug levels, the phenytoin dose does not need 
to be increased. 
Metabolic interactions may involve either 
induction or inhibition of biotransformation 
processes. The increased elimination of val- 
proic acid, lamotrigine, theophylline and pred- 
nisolone in patients treated concurrently with 
carbamazepine, phenytoin or barbiturates 
provide good examples of clinically significant 
enzyme induction. Conversely, the rise in 
serum concentration of lamotrigine or pheno- 
barbitone in patients treated with valproic 
acid, or the precipitation of carbamazepine in-
toxication by erythromycin, are important 
examples of metabolic inhibitory interactions 
(Table 3). 
Renally eliminated rugs such as gabapen- 
tin and vigabatrin are much less liable to be 
involved in drug interactions. However, a de- 
crease in serum phenytoin concentration after 
addition of vigabatrin has been described. 
Pharmacodynamic drug interactions 
Pharmacodynamic interactions may result in 
synergism or antagonism at the site of action. 
These interactions generally have adverse 
clinical consequences, the best example being 
represented by the possible development of 
drug intoxication in children receiving a com- 
bination of several anticonvulsants, despite 
low doses and low serum concentrations of the 
individual agents. Favourable pharmacody- 
namic interactions have also been reported. 
The best documented example involves val- 
proic acid and ethosuximide, whose combi- 
nation may prove remarkably effective in 
patients with absence seizures refractory to 
either drug given alone 13. 
CONCLUSION 
Rational therapy of epilepsy in children re- 
quires a good knowledge of the clinical phar- 
macology of the various anticonvulsants. In
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particular, drug selection should take into con- 
sideration not only the spectrum of efficacy, 
but also the toxicity profile of individual 
agents. Children differ from adults in dosage 
requirements and in susceptibility to particu- 
lar aspects of drug toxicity, and careful moni- 
toring of clinical response is required to ensure 
optimal seizure suppression without excessive 
adverse effects. 
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